Company intelligence / Profile preview

Fermbox Bio

Atlanta, Georgia, United Statesfermbox.bio ↗

Ownership: Private
Development stage: Other

Overview

Fermbox Bio develops sustainable synthetic biology-based biomaterials using precision fermentation. The company has commercialized at least one product—EN3ZYME—for efficient conversion of agricultural residues to fermentable sugars. It offers end-to-end Synbio solutions from R&D to large-scale manufacturing for industries including food/nutrition, cosmeceuticals, and green chemicals.

Therapeutic areas: DermatologyMetabolic DisordersOther
Modalities: Enzyme replacement therapyProteinSmall moleculeMicrobial therapyLipid nanoparticle delivery therapyRecombinant protein
Industry: Non-Drug Biotech

Partnerships

BBGI – strategic joint venture in Thailand/Southeast Asia for large-scale precision fermentation plant development

Beyond the preview

Go deeper on Fermbox Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fermbox Bio.

Explore the full profile